The New York Entrepreneur

Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Read Time:5 Second

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Comcast is set to report earnings before the bell. Here’s what Wall Street expects
Next post Chip sector due a May bounce with Nvidia near ‘trough valuation,’ says Bank of America strategists